Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
51 Results for "
NO/cGMP pathway
" in MedChemExpress (MCE) Product Catalog:
Products (51)
51 Results for "NO/cGMP pathway" in MCE Product Catalog:
10
10 Publications Verification
Synonyms: (±)-α-Lipoamide; DL-Lipoamide; DL-6,8-Thioctamide
Category:
Human Gut Microbiota Metabolites Natural Products Microorganisms Other Diseases Endogenous metabolite Disease Research Fields
Target:
7
7 Cited Publications
Synonyms: AT2 receptor agonist C21
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis .
3
2
Target:
Research Areas:
Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytokines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure .
2
Category:
Flavonoids Flavones Cruciferae Isatis tinctoria L. Phenols Polyphenols Plants Disease Research Fields Cancer
Target:
2
2 Cited Publications
Cat. No.: HY-W013386
CAS No.: 91300-60-6
Target:
Research Areas:
LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .
2
Category:
Cardiovascular Disease Flavonols Flavonoids Croton tiglium Linn. Phenols Polyphenols Euphorbiaceae Plants Disease Research Fields
Target:
1
1
1 Cited Publications
Synonyms: Delphinidin 3-O-rutiNOside chloride
1
1 Cited Publications
Cat. No.: HY-P10869
Research Areas:
Target:
Research Areas:
Pamabrom is a diuretic that acts on the opioid receptor-nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K + channel pathway. Pamabrom exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea[1].
Cat. No.: HY-N4246
CAS No.: 382148-47-2
Cat. No.: HY-N3320
CAS No.: 14957-38-1
Target:
Cat. No.: HY-120314
CAS No.: 144576-10-3
Target:
Research Areas:
GEA 3162 is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 can be used for research on inflammatory conditions such as gastric ulcers .
Cat. No.: HY-153092
CAS No.: 1579514-06-9
Synonyms: BI-685509
Target:
Research Areas:
Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .
Cat. No.: HY-P1556
CAS No.: 141676-35-9
Target:
Research Areas:
Cat. No.: HY-18252A
CAS No.: 330784-48-0
Synonyms: TA1790 dibenzenesulfonate
Cat. No.: HY-19116
CAS No.: 134431-49-5
Target:
Research Areas:
KRN-2391 is a KATP channel opener with NO donor properties. KRN-2391 exerts dual inhibitory effects on overactive bladder (OAB) by activating KATP channels (causing cellular hyperpolarization and bladder smooth muscle relaxation) and releasing NO (enhancing relaxation via cGMP pathways). KRN-2391 is promising for research of OAB .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
